e-learning
resources
Barcelona 2010
Monday, 20.09.2010
Biomarkers for lung cancer
Login
Search all ERS
e-learning
resources
Disease Areas
Airways Diseases
Interstitial Lung Diseases
Respiratory Critical Care
Respiratory Infections
Paediatric Respiratory Diseases
Pulmonary Vascular Diseases
Sleep and Breathing Disorders
Thoracic Oncology
Events
International Congress
Courses
Webinars
Conferences
Research Seminars
Journal Clubs
Publications
Breathe
Monograph
ERJ
ERJ Open Research
ERR
European Lung White Book
Handbook Series
Guidelines
All ERS guidelines
e-learning
CME Online
Case reports
Short Videos
SpirXpert
Procedure Videos
CME tests
Reference Database of Respiratory Sounds
Radiology Image Challenge
Brief tobacco interventions
EU Projects
VALUE-Dx
ERN-LUNG
ECRAID
UNITE4TB
Disease Areas
Events
Publications
Guidelines
e-learning
EU Projects
Login
Search
Contribution of genetic polymorphism of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, to the susceptibility and severity of non-small cell lung cancer
Y. L. Lee, W. Chen, W. E. Cheng, S. C. Chen, C. M. Shih (Taichung, Taiwan)
Source:
Annual Congress 2010 - Biomarkers for lung cancer
Session:
Biomarkers for lung cancer
Session type:
Thematic Poster Session
Number:
3240
Disease area:
Thoracic oncology
Rating:
You must
login
to grade this presentation.
Share or cite this content
Citations should be made in the following way:
Y. L. Lee, W. Chen, W. E. Cheng, S. C. Chen, C. M. Shih (Taichung, Taiwan). Contribution of genetic polymorphism of stromal cell-derived factor-1 (SDF-1) and its receptor, CXCR4, to the susceptibility and severity of non-small cell lung cancer. Eur Respir J 2010; 36: Suppl. 54, 3240
You must
login
to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
No comment yet.
You must
Login
to comment this presentation.
Related content which might interest you:
Observational cohort study of pulmonary exacerbations in alpha-1 antitrypsin deficiency
Panel discussion: ICU admission of lung cancer patients – Is COVID-19 a game-changer?
Surgical vs non-surgical treatment of early stage non-small cell lung cancer: here's the fight
Related content which might interest you:
Genetic profiling and epidermal growth factor receptor-directed therapy in nonsmall cell lung cancer
Source: Eur Respir J 2011; 37: 183-193
Year: 2011
The effect of adhesion molecule CEACAM1 and chemokine receptor CXCR4 expression on prognosis of non-small cell lung cancer
Source: Eur Respir J 2005; 26: Suppl. 49, 324s
Year: 2005
Expression of tumor necrosis factor receptor 2 in human non-small cell lung cancer and its role as a potential prognostic biomarker
Source: International Congress 2019 – Biology of lung cancer
Year: 2019
Macrophage expression of interleukin-10 is a prognostic factor in nonsmall cell lung cancer
Source: Eur Respir J 2007; 30: 627-632
Year: 2007
Expression of angiogenic growth factors and stromal cell derived factor-1/CXC chemokine receptor 4 (SDF-1/CXCL12 – CXCR4) biological axis in idiopathic pulmonary fibrosis: a lung tissue study
Source: Annual Congress 2008 - New insights into the pathogenesis of idiopathic pulmonary fibrosis and sarcoidosis
Year: 2008
Expression of vascular endothelial growth factor (VEGF) and its receptors (VEFG-R1-Flt1, VEGF-R2-Flk1) in non small cell lung carcinomas (NSCLC): correlation with lymphangiogenesis and clinical outcome
Source: Annual Congress 2007 - Diagnosis and prognosis in thoracic oncology
Year: 2007
Prognostic significance of epidermal growth factor receptor expression in nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 72s
Year: 2002
Increased expression of angiogenic growth factor stromal cell derived factor-1 (SDF-1/CXCL12) in pleural fluid of patients with lung cancer: preliminary results
Source: Annual Congress 2008 - Biology and prognosis in thoracic oncology
Year: 2008
Epidermal growth factor receptor (EGFR) expression in operable non-small cell lung cancer and its correlation with survival
Source: Annual Congress 2009 - Genetics in the smokers corner: from inflammation in smokers via COPD to cancer
Year: 2009
Polymorphisms in the interleukin-10 gene promoter are associated with susceptibility to non-small cell lung cancer (NSCLC)
Source: Eur Respir J 2005; 26: Suppl. 49, 458s
Year: 2005
Inverse correlation between the expression of vascular endothelial growth factor and infiltration of dendritic cells and their influence on the prognosis of nonsmall cell lung cancer
Source: Eur Respir J 2002; 20: Suppl. 38, 13s
Year: 2002
The prognostic value of serum epidermal growth factor receptor (EGFR) levels in patients with non-small cell lung cancer
Source: Eur Respir J 2004; 24: Suppl. 48, 674s
Year: 2004
A blood-based test for epidermal growth factor receptor mutations in patients with non-small cell lung cancer
Source: Annual Congress 2008 - Therapy in thoracic oncology
Year: 2008
Expression of vascular endothelial growth factor (VEGF) and association with lymphangiogenesis in non small cell (NSCLC) and small cell lung carcinomas (SCLC)
Source: Eur Respir J 2006; 28: Suppl. 50, 386s
Year: 2006
LATE-BREAKING ABSTRACT: Expression of macrophage migration inhibitory factor (MIF) in the serum and lung tissues in patients with non-small cell lung cancer (NSCLC)
Source: Annual Congress 2012 - Prognosis of lung cancer
Year: 2012
Clinical features associated with epidermal growth factor receptor and K-RAS gene mutations in non-small cell lung cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 811s
Year: 2006
Targeting gene of insulin-like growth factor type I (IGF-I) on
in vitro
model of A549 cell line with triple-helix approach. Perspectives of gene therapy in non-small cell lung (NSCLC) cancer
Source: Eur Respir J 2006; 28: Suppl. 50, 387s
Year: 2006
Prognostic role of epidermal growth factor receptor in stage III nonsmall cell lung cancer
Source: Eur Respir J 2005; 25: 329-335
Year: 2005
Toll-like receptor 3 is up-regulated and enhances anti-proliferative function in human non-small cell lung cancer
Source: Annual Congress 2008 - Lung cancer and other malignant diseases involving the lungs
Year: 2008
Increased vascular-endothelial growth factor a (VEGF-A) expression and response to angiogenesis inhibitor erlotinib in non-small-cell lung cancer (NSCLC) – hint for a new predictive marker?
Source: Annual Congress 2007 - Therapeutic approaches in thoracic oncology
Year: 2007
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking "Accept", you consent to the use of the cookies.
Accept